Scarica l'app Stockscreener
36.12
1.91%
-0.705
Pre-mercato:
36.30
0.175
+0.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$36.83
Aprire:
$36.94
Volume 24 ore:
1.44M
Relative Volume:
0.67
Capitalizzazione di mercato:
$5.73B
Reddito:
$264.79M
Utile/perdita netta:
$-14.36M
Rapporto P/E:
-328.41
EPS:
-0.11
Flusso di cassa netto:
$-28.11M
1 W Prestazione:
+1.56%
1M Prestazione:
+23.17%
6M Prestazione:
-8.38%
1 anno Prestazione:
+54.45%
Intervallo 1D:
$35.95
$37.11
Intervallo di 1 settimana:
$34.52
$37.15
Portata 52W:
$21.16
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Nome
Tg Therapeutics Inc
Settore
Industria
Telefono
(212) 554-4484
Indirizzo
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Confronta TGTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
36.12 | 5.84B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2024-10-29 | Iniziato | TD Cowen | Buy |
| 2023-08-02 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-26 | Ripresa | Jefferies | Buy |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-01 | Iniziato | JP Morgan | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Iniziato | Evercore ISI | Outperform |
| 2020-01-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2018-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Ripresa | H.C. Wainwright | Buy |
| 2017-04-25 | Iniziato | Jefferies | Buy |
| 2017-03-06 | Reiterato | FBR & Co. | Outperform |
| 2016-10-06 | Ripresa | Brean Capital | Buy |
| 2016-05-27 | Iniziato | SunTrust | Buy |
| 2015-12-01 | Iniziato | FBR Capital | Outperform |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-19 | Reiterato | Brean Capital | Buy |
| 2014-12-11 | Reiterato | ROTH Capital | Buy |
| 2014-12-10 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
Is TG Therapeutics Inc. forming a bottoming base2025 Macro Impact & Technical Confirmation Alerts - newser.com
Can TG Therapeutics Inc. stock rebound after recent weakness2025 Year in Review & Free Expert Verified Stock Movement Alerts - newser.com
Detecting support and resistance levels for TG Therapeutics Inc.2025 Risk Factors & Smart Money Movement Alerts - newser.com
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - simplywall.st
Key metrics from TG Therapeutics Inc.’s quarterly dataProfit Target & Fast Gain Swing Trade Alerts - newser.com
What indicators show strength in TG Therapeutics Inc.Exit Point & Consistent Return Investment Signals - newser.com
What makes TG Therapeutics Inc. (NKB2) stock appealing to growth investorsEntry Point & Low Risk Entry Point Tips - newser.com
Analyzing TG Therapeutics Inc. with risk reward ratio chartsJuly 2025 Earnings & Capital Efficiency Focused Ideas - newser.com
TG Therapeutics, Inc. (TGTX) Investor Outlook: Strong Revenue Growth and Promising Pipeline Signal Potential Upside - DirectorsTalk Interviews
TG Therapeutics, Inc. (TGTX) Investor Outlook: Riding On A 92.10% Revenue Growth Wave - DirectorsTalk Interviews
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN
What drives TG Therapeutics Inc stock priceGlobal Trade Effects & Low Risk Capital Growth Plans - earlytimes.in
Is TG Therapeutics Inc a good long term investmentHead and Shoulders Patterns & Demo Trading Rooms Open Daily - Early Times
What analysts say about TG Therapeutics Inc stockStock Valuation Metrics & Backtest Your Strategy Before You Risk Money - earlytimes.in
How risky is TG Therapeutics Inc. (NKB2) stock compared to peers2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Tg Therapeutics And Ke Holdings Top The Bull Strangle Watch List For This Week - Barchart.com
TG Therapeutics’ MS drug shows low relapse rate after six years By Investing.com - Investing.com South Africa
TG Therapeutics’ MS drug shows low relapse rate after six years - Investing.com India
TGTX Shares Rise on Promising Six-Year Data from ULTIMATE Trials - GuruFocus
TG Therapeutics Says 6-Year Briumvi Data Show 90% of Multiple Sclerosis Patients Free From Progression - MarketScreener
TG Therapeutics Reports Six-Year Data for BRIUMVI® Showing Exceptional Efficacy and Consistent Safety Profile in Multiple Sclerosis Treatment - Quiver Quantitative
New Data for BRIUMVI® Demonstrate 89.9% of Patients with - GlobeNewswire
Breakthrough: MS Drug Keeps 90% of Patients Disability-Free for 6 YearsTG Therapeutics' BRIUMVI Sets New Bar - Stock Titan
TG Therapeutics Hits Day High with Strong 8.03% Intraday Surge - Markets Mojo
19,900 Shares in TG Therapeutics, Inc. $TGTX Bought by Strs Ohio - MarketBeat
TG Therapeutics (TGTX): Evaluating Valuation After New Phase 3 BRIUMVI Trial Launch - Sahm
What is B. Riley's Estimate for TG Therapeutics Q3 Earnings? - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00 - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Bull Run: Can TG Therapeutics Inc maintain sales growthMarket Growth Summary & Low Risk Profit Maximizing Plans - خودرو بانک
Strs Ohio Makes New Investment in TG Therapeutics, Inc. $TGTX - Defense World
What is B. Riley's Estimate for TG Therapeutics Q4 Earnings? - MarketBeat
Voya Investment Management LLC Has $11.85 Million Position in TG Therapeutics, Inc. $TGTX - MarketBeat
What is B. Riley’s Forecast for TG Therapeutics Q4 Earnings? - Defense World
Day Trade: Will TG Therapeutics Inc outperform tech stocksWeekly Trend Report & Weekly Stock Breakout Alerts - خودرو بانک
Short Squeeze: Should you avoid ProShares Trust ProShares Ultra Materials stock right now2025 Volume Leaders & Reliable Volume Spike Trade Alerts - khodrobank.com
B. Riley Has Bearish Outlook for TG Therapeutics Q3 Earnings - Defense World
Market Review: What are TG Therapeutics Incs recent SEC filings showingEarnings Overview Report & Daily Entry Point Alerts - khodrobank.com
Institution Moves: Does TG Therapeutics Inc stock benefit from AI growth2025 Fundamental Recap & Weekly Return Optimization Alerts - khodrobank.com
TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00 at B. Riley - Defense World
Intech Investment Management LLC Increases Stock Holdings in TG Therapeutics, Inc. $TGTX - MarketBeat
Sentiment Review: Can TG Therapeutics Inc. sustain its profitabilityWeekly Investment Recap & AI Forecast for Swing Trade Picks - khodrobank.com
TG Therapeutics rises 17% as 2025 revenue guidance, Q4 revenue beats expectations - MSN
TGTX: B. Riley Securities Raises Price Target on TG Therapeutics - GuruFocus
How cyclical is TG Therapeutics Inc.’s revenue streamWeekly Stock Recap & Free Risk Controlled Daily Trade Plans - خودرو بانک
B. Riley Raises Price Target on TG Therapeutics to $55 From $53, Keeps Buy Rating - MarketScreener
Focus Partners Wealth Boosts Stock Holdings in TG Therapeutics, Inc. $TGTX - Defense World
Quarterly Trades: Is TG Therapeutics Inc undervalued by DCF analysis2025 Macro Impact & Weekly High Return Stock Forecasts - خودرو بانک
TG Therapeutics (NASDAQ:TGTX) Director Sagar Lonial Sells 20,852 Shares - MarketBeat
Bull Bear: Is Urgent.ly Inc. a potential multi baggerRate Hike & Daily Profit Maximizing Tips - خودرو بانک
Will TG Therapeutics Inc benefit from AI trends2025 Key Lessons & Weekly High Return Stock Forecasts - خودرو بانک
Tg Therapeutics Inc Azioni (TGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):